Management of patients with hepatitis B virus-induced cirrhosis

Journal of Hepatology

Volumn 42, Issue SUPPL. 1, 2005, Pages

  Fung, Scott K ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIVIRUS AGENT; DNA; EMTRICITABINE; ENTECAVIR; HEPATITIS E ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR DISOPROXIL;

CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DELTA AGENT HEPATITIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DNA HYBRIDIZATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INFECTION RISK; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; SEROCONVERSION; SIDE EFFECT; SURVIVAL RATE; VIRUS DETECTION; VIRUS REPLICATION; VIRUS SURVIVAL;

EID: 14944364517     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.11.014     Document Type: Review

References (84)

1. G. Fattovich Natural history of hepatitis B J Hepatol 39 2003 50 58
2. Y.F. Liaw, D.I. Tai, C.M. Chu, and T.J. Chen The development of cirrhosis in patients with chronic type B hepatitis: a prospective study Hepatology 8 1988 493 496
3. J.H. Hoofnagle, A.M. Di Bisceglie, J.G. Waggoner, and Y. Park Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B Gastroenterology 104 1993 1116 1121
4. R. Perrillo, C. Tamburro, F. Regenstein, L. Balart, H. Bodenhemier, and M. Silva Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus Gastroenterology 109 1995 908 916
5. R.P. Perrillo, T. Wright, J. Rakela, G. Levy, E. Schiff, and R. Gish A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B Hepatology 33 2001 424 432
6. F.Y. Yao, N.A. Terrault, C. Freise, L. Maslow, and N.M. Bass Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort Hepatology 34 2001 411 416
7. E. Schiff, C.L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, and M. Colombo Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients Hepatology 38 2003 1419 1427
8. P. Andreone, M. Biselli, A. Gramenzi, C. Cursaro, M.C. Morelli, and C. Sama Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation Transplantation 74 2002 1119 1124
9. J.P. Villeneuve, L. Condreay, B. Willems, G. Pomier-Layrargues, D. Fenyves, and M. Bilodeau Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B Hepatology 31 2000 207 210
10. G. Fattovich, L. Brollo, G. Giustina, F. Noventa, P. Pontisso, and A. Alberti Natural history and prognostic factors of chronic hepatitis type B Gut 32 1991 294 298
11. G. Fattovich, G. Giustina, G. Realdi, R. Corrocher, S.W. Schalm, and European Concerted Action On Viral Hepatitis (EUROHEP) Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa Hepatology 26 1997 1338 1342
12. Y.F. Liaw, D.I. Tai, C.M. Chu, and T.J. Chen The development of cirrhosis in patients with chronic type B hepatitis: a prospective study Hepatology 8 1988 493 496
13. G. Fattovich, L. Brollo, A. Alberti, P. Pontisso, G. Giustina, and G. Realdi Long-term follow-up of anti-HBe-positive chronic active hepatitis B Hepatology 8 1988 1651 1654
14. J.F. Colin, D. Cazals-Hatem, M.A. Loriot, M. Martinot-Peignoux, B.N. Pham, and A. Auperin Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men Hepatology 29 1999 1306 1310
15. K. Ikeda, S. Saitoh, Y. Suzuki, M. Kobayashi, A. Tsubota, and I. Koida Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients J Hepatol 28 1998 930 938
16. E. Sagnelli, N. Coppola, C. Scolastico, P. Fillipini, T. Sanantonio, and T. Stroffolini Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis Hepatology 32 2000 1106 1110
17. C. Chu, M. Hussain, and A. Lok Hepatitis B virus genotype B is associated with earlier spontaneous seroconversion than hepatitis B virus genotype C Gastroenterology 122 2003 1756 1762
18. H. Sumi, O. Yokosuka, N. Seki, M. Arai, F. Imazeki, and T. Kurihara Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease Hepatology 37 2003 19 26
19. G. Fattovich, M. Pantalena, I. Zagni, G. Realdi, S.W. Schalm, E. Christensen, and European Concerted Action On Viral Hepatitis (EUROHEP) Effect of hepatitis B and hepatitis C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients Am J Gastroenterol 97 2002 2886 2895
20. F.E. De Jongh, H.L. Janssen, R.A. de Man, W.C.J. Hop, S.W. Schalm, and M. Van Blankenstein Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver Gastroenterology 103 1992 1630 1635
21. F. Donato, A. Tagger, R. Chiesa, M.L. Ribero, V. Tomasoni, and M. Fasola Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy Hepatology 26 1997 579 584
22. R.P. Beasley Hepatitis B virus: the major etiology of hepatocellular carcinoma Cancer 61 1988 1942 1956
23. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
24. B. McMahon, S.R. Alberts, R.B. Wainwright, L. Bulkow, and A.P. Lanier Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaskan Native carriers Arch Intern Med 150 1990 1051 1054
25. G. Fattovich, G. Giustina, S.W. Schalm, S. Hadziyannis, J.M. Sanchez-Tapias, and P. Almasio Occurrence of hepatocellular carcinoma and decompensation in Western patients with cirrhosis type B. The EUROHEP Study Group on hepatitis B virus and cirrhosis Hepatology 21 1995 77 82
26. L. Benvegnu, G. Fattovich, F. Noventa, F. Tremolada, L. Chemello, and A. Cecchetto Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study Cancer 74 1994 2242 2248
27. Z. Sun, P. Lu, and M.H. Gail Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1 Hepatology 30 1999 379 383
28. M.C. Yu, M. Tong, S. Govindarajan, and B.E. Henderson Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California J Natl Cancer Inst 83 1991 1820 1826
29. H.I. Yang, S.N. Lu, Y.F. Liaw, S.L. You, C.A. Sun, and L.Y. Wang Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 2002 168 174
30. M. Manno, C. Camma, F. Schepis, F. Bassi, R. Gelmini, and F. Giannini Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years Gastroenterology 127 2004 756 763
31. M.R. Arguedas, A. Johnson, M.A. Eloubeidi, and M.B. Fallon Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients Hepatology 34 2001 28 31
32. Lok ASF, McMahon B. AASLD Practice guidelines: chronic hepatitis B. http://www.aasld org/eweb/docs/update_chronichep_B pdf ; 2004.
33. B.J. McMahon, L. Bulkow, A. Harpster, M. Snowball, A. Lanier, and F. Sacco Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study Hepatology 32 2000 842 846
34. M. Sherman, K.M. Peltekian, and C. Lee Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population Hepatology 22 1995 432 438
35. B. Yang, B. Zhang, Y. Xu, W. Wang, Y. Shen, and A. Zhang Prospective study of early detection for primary liver cancer J Cancer Res Clin Oncol 123 1997 357 360
36. M.F. Yuen, C.C. Cheng, I.J. Lauder, S.K. Lam, C.G.C. Ooi, and C.L. Lai Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience Hepatology 31 2000 330 335
37. F. Trevisani, P.E. D'Intino, A.M. Morselli-Labate, G. Mazzella, E. Accogli, and P. Caraceni Serum alfa-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status J Hepatol 34 2001 570 575
38. A.S. Lok, and C.L. Lai Alfa-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma Hepatology 9 1989 110 115
39. D.S. Chen, J.S. Sung, J.C. Sheu, M.Y. Lai, S.W. How, and H.C. Hsu Serum alfa-fetoprotein in the early stage of human hepatocellular carcinoma Gastroenterology 86 1984 1404 1409
40. J. Bruix, and J.M. Llovet Hepatitis B virus and hepatocellular carcinoma J Hepatol 39 2003 S59 S63
41. J.C. Sheu, J.L. Sung, D.S. Chen, P.M. Yang, M.Y. Lai, and C.S. Lee Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications Gastroenterology 89 1985 259 266
42. X.D. Zhou, Z.Y. Tang, B.H. Yang, Z.Y. Lin, Z.C. Ma, and S.C. Ye Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma Cancer 91 2001 1479 1486
43. P. Lampertico, E. Del Ninno, M. Vigano, R. Romeo, M. Donato, and E. Sablon Long term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 2003 756 763
44. A.S. Lok, P.C. Wu, C.L. Lai, J.Y. Lau, E.K. Leung, and L.S. Wong A controlled trial of interferon with or without prednisone priming for chronic hepatitis B Gastroenterology 102 1992 2091 2097
45. R. Perrillo, E. Schiff, D. Davis, H. Bodenhemier, K. Lindsay, J. Payne, and Hepatitis Interventional Therapy Group A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B N Engl J Med 323 1990 295 301
46. W.G.E. Cooksley, T. Piratvisuth, S.D. Lee, V. Mahachai, Y.C. Chao, and T. Tanwandee Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 2003 298 305
47. P. Lampertico, E. Del Ninno, M. Vigano, R. Romeo, M. Donato, and E. Sablon Long-Term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 2003 756 763
48. D.T. Lau, J.E. Everhart, D.E. Kleiner, Y. Park, J. Vergalla, and P. Schmid Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1997 1660 1667
49. S.M. Lin, I.S. Sheen, R.N. Chien, C.M. Chu, and Y.F. Liaw Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 1999 971 975
50. C. Niederau, T. Heintges, S. Lange, G. Goldmann, C.M. Niederau, and L. Mohr Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422 1427
51. G. Papatheodoridis, E.K. Manesis, and S.J. Hadziyannis The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2001 306 313
52. M.F. Yuen, C.K. Hui, C.C. Cheng, C.H. Wu, Y.P. Lai, and C.L. Lai Long-term follow-up of Interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect of hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 2001 139 145
53. M. van Zonneveld, P. Honkoop, B.E. Hansen, H.G.M. Niesters, S. Darwish Murad, and R.A. de Man Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatology 39 2004 804 810
54. J. Dienstag, E. Schiff, T. Wright, R. Perrillo, H. Hann, and Z. Goodman Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
55. C.L. Lai, R.N. Chien, N. Leung, T.T. Chang, R. Guan, and D.I. Tai A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 1998 61 68
56. N. Tassopoulos, R. Volpes, G. Pastore, J. Heathcote, M. Buti, and R. Goldin Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Hepatology 29 1999 889 896
57. J. Dienstag, R. Goldin, E.J. Heathcote, H. Hann, M. Woessner, and S.L. Stephenson Histological outcome during long-term lamivudine therapy Gastroenterology 124 2003 105 117
58. G. Papatheodoridis, E. Dimou, A. Laras, V. Papadimitropoulos, and S. Hadziyannis Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease Hepatology 32 2002 219 226
59. Y.F. Liaw, J.J.Y. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
60. R.J. Fontana, E. Keeffe, W. Carey, M. Fried, R. Reddy, and K. Kowdley Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B Liver Transpl 8 2002 433 439
61. D. Kapoor, R.C. Guptan, S.M. Wakil, S.N. Kazim, R. Kaul, and S.R. Agarwal Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis J Hepatol 33 2000 308 312
62. R.J. Fontana, H.W. Hann, R.P. Perrillo, J.M. Vierling, T. Wright, and J. Rakela Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy Gastroenterology 123 2002 719 727
63. T.T. Chang, C.L. Lai, R.N. Chien, R. Guan, S.G. Lim, and C.M. Lee Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 2004 1276 1282
64. N.W. Leung, C.L. Lai, T.T. Chang, R. Guan, C.M. Lee, and K.Y. Ng Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 2001 1527 1532
65. Y.F. Liaw, N.W. Leung, T.T. Chang, R. Guan, D.I. Tai, and K.Y. Ng Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 119 2000 172 180
66. N. Ogata, K. Fujii, S. Takigawa, M. Nomoto, T. Ichida, and H. Asakura Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B J Med Virol 59 1999 270 276
67. R.A. de Man, A. Bartholomeusz, H.G.M. Niesters, P.E. Zondervan, and S.A. Locarnini The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss J Hepatol 29 1998 669 675
68. J. Rosenau, M.J.H. Bahr, H.L. Tillmann, C. Trautwein, J. Klempnauer, and M. Manns Lamivudine and low dose hepatitis B immune globulin as prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection J Hepatol 43 2001 895 902
69. D. Seehofer, N. Rayes, T. Steinmuller, A.R. Muller, U. Settmacher, and R. Neuhaus Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation Liver Transpl 7 2001 976 982
70. M. Peters, H.W. Hann, P. Martin, E.J. Heathcote, P. Buggisch, and R. Rubin Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
71. S. Locarnini Hepatitis B viral resistance: mechanisms and diagnosis J Hepatol 39 2003 S124 S132
72. J. Torresi, L. Earnest-Silveira, G. Deliyannis, K. Edgtton, H. Zhuang, and S. Locarnini Vaccine-induced anti-HBs escape mutants of hepatitis B virus arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy Virology 293 2002 305 313
73. S. Hadziyannis, N. Tassopoulos, J. Heathcote, T.-T. Chang, G. Kitis, and M. Rizzetto Adefovir Dipivoxil for the treatment of hepatitis B e-antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
74. P. Marcellin, T.T. Chang, S.G. Lim, M. Tong, W. Sievert, and M. Schiffman Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
75. Z. Goodman, P. Marcellin, T.T. Chang, S.G. Lim, M. Tong, and W. Sievert 48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg+ chronic hepatitis B (abstract) Hepatology 36 2003 373A
76. E. Schiff, C.L. Lai, P. Neuhaus, H. Tillmann, D. Samuel, and J.P. Villeneuve Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation (OLT) with lamivudine-resistant (LAM-R) hepatitis B virus (HBV) patients (abstract) Hepatology 36 2003 371A
77. C.E. Westland, H. Yang, W.E. Delaney, C.S. Gibbs, M.D. Miller, M. Wulfsohn, and 437 and 438 Study Teams Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B Hepatology 38 2003 96 103
78. P. Angus, R. Vaughan, S. Xiong, H. Yang, W.E. Delaney, and C.S. Gibbs Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2003 292 297
79. X. Qi, A. Snow, V. Thibault, Y. Zhu, M. Curtis, and S. Hadziyannis Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy (abstract) J Hepatol 40 2004 A57
80. R. Gish, T. Chang, S. Hadziyannis, J. Cianciara, M. Rizzetto, and E. Schiff Lamivudine-refractory hepatitis B patients can be safely switched to entecavir 1 mg daily therapy (abstract) J Hepatol 40 2004 A428
81. C.L. Lai, M. Rosmawati, J. Lao, H. Van Vlierberghe, F. Anderson, and N. Thomas Entecavir is superior to lamivudine in reducing hepatitis B DNA in patients with chronic hepatitis B infection Gastroenterology 123 2002 1831 1838
82. A.O. Shakil, L. Lilly, P. Angus, G. Gerken, N. Thomas, and M. Jean Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B (abstract) Hepatology 34 2001 619A
83. D.J. Tenney, S. Levine, R. Rose, A.W. Walsh, S.P. Weinheimer, and L. Discotto Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 2004 3498 3507
84. M.B. Ristig, J. Crippin, J.A. Aberg, W.G. Powderly, M. Lisker-Melman, and L. Kessels Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alfa and lamivudine therapy have failed J Infect Dis 186 2002 1844 1847